Showing 781-800 of 8668 for: Cochrane Systematic Reviews Back
- Antistreptococcal interventions for guttate and chronic plaque psoriasis
Cochrane Systematic Reviews, 6-Mar-2019
Guttate psoriasis is a distinctive acute form of psoriasis which characteristically occurs in children and young adults. It is closely associated with preceding streptococcal sore throat or tonsillitis. Some authorities have claimed that ordinary (chronic
- Antithrombin for respiratory distress syndrome in preterm infants
Cochrane Systematic Reviews, 24-Jan-2010
Acquired Antithrombin (AT) deficiency is a common and prognostically important finding in sick preterm infants with respiratory distress syndrome (RDS). It has been hypothesised that AT concentrate may improve clinical outcomes in preterm infants with RDS
- Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants
Cochrane Systematic Reviews, 21-Mar-2016
Preterm birth remains the major risk factor for the development of intraventricular hemorrhage, an injury that occurs in 25% of very low birth weight infants. Intraventricular hemorrhage is thought to be venous in origin and intrinsic thromboses in the ge
- Antithrombin III for critically ill patients
Cochrane Systematic Reviews, 9-Feb-2016
Critical illness is associated with uncontrolled inflammation and vascular damage which can result in multiple organ failure and death. Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties but the efficacy and any harmful effect
- Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery
Cochrane Systematic Reviews, 15-Jun-2011
Peripheral arterial disease (PAD) is frequently treated by either an infrainguinal autologous (using the patient's own veins) or synthetic graft bypass. The rate of occlusion of the graft after one year is between 12% and 60%. To prevent occlusion, patien
- Antithrombotic drugs for carotid artery dissection
Cochrane Systematic Reviews, 6-Mar-2011
Extracranial internal carotid artery dissection (eICAD) is a leading cause of stroke in younger patients.
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
Cochrane Systematic Reviews, 28-Sep-2021
Multiple myeloma is a malignant plasma cell disorder characterised by clonal plasma cells that cause end-organ damage such as renal failure, lytic bone lesions, hypercalcaemia and/or anaemia. People with multiple myeloma are treated with immunomodulatory
- Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction
Cochrane Systematic Reviews, 17-Jul-2013
Pregnancy complications such as pre-eclampsia and eclampsia, intrauterine growth restriction and placental abruption are thought to have a common origin related to abnormalities in the development and function of the placenta.
- Antithrombotic treatment after stroke due to intracerebral haemorrhage
Cochrane Systematic Reviews, 25-May-2017
Survivors of stroke due to intracerebral haemorrhage (ICH) are at risk of thromboembolism. Antithrombotic (antiplatelet or anticoagulant) treatments may lower the risk of thromboembolism after ICH, but they may increase the risks of bleeding.
- Antithyroid drug regimen for treating Graves' hyperthyroidism
Cochrane Systematic Reviews, 20-Jan-2010
Antithyroid drugs are widely used in the therapy of hyperthyroidism. There are wide variations in the dose, regimen or duration of treatment used by health professionals.
- Anti‐TNF agents for paediatric psoriasis
Cochrane Systematic Reviews, 24-Nov-2015
Psoriasis is a chronic skin disease that may develop at any age. Estimates for the United States and Europe suggest that psoriasis accounts for 4% of skin diseases in children. In most cases, the condition is mild and can be treated with creams. However,
- Anti‐TNF‐α treatment for pelvic pain associated with endometriosis
Cochrane Systematic Reviews, 28-Mar-2013
Endometriosis is a chronic, recurring condition that can develop during the reproductive years. It is characterised by the development of endometrial tissue outside the uterine cavity. It is the most common cause of pelvic pain in women. This endometrial
- Anti‐tuberculous therapy for maintenance of remission in Crohn's disease
Cochrane Systematic Reviews, 22-Jul-2016
There have been a number of studies with conflicting results which have examined the effect of anti-tuberculous therapy in Crohn's disease. A meta-analysis was performed to evaluate the use of anti-tuberculous therapy for the maintenance of remission in C
- Antitumour antibiotic containing regimens for metastatic breast cancer
Cochrane Systematic Reviews, 18-Oct-2004
Antitumour antibiotics are used in the management of metastatic breast cancer. Some of these agents have demonstrated higher tumour response rates than non-antitumour antibiotic regimens, however a survival benefit has not been established in this setting
- Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis
Cochrane Systematic Reviews, 18-Dec-2018
Non-infectious uveitis describes a heterogenous group of ocular disorders characterised by intraocular inflammation in the absence of infection. Uveitis is a leading cause of visual loss, most commonly due to uveitic macular oedema (UMO). Treatment is aim
- Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity
Cochrane Systematic Reviews, 8-Jan-2018
Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in foetal life. Researchers have recently attempted to use anti-VEGF agents for the treatment of retinopathy of prematurity (ROP), a vasoproliferative disorder. The safety and effi
- Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema
Cochrane Systematic Reviews, 18-Apr-2018
The combination of steroid and anti-vascular endothelial growth factor (VEGF) intravitreal therapeutic agents could potentially have synergistic effects for treating diabetic macular oedema (DMO). On the one hand, if combined treatment is more effective t
- Anti‐vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia
Cochrane Systematic Reviews, 15-Dec-2016
Choroidal neovascularisation (CNV) is a common complication of pathological myopia. Once developed, most eyes with myopic CNV (mCNV) experience a progression to macular atrophy, which leads to irreversible vision loss. Anti-vascular endothelial growth fac
- Anti‐vascular endothelial growth factor for control of wound healing in glaucoma surgery
Cochrane Systematic Reviews, 15-Jan-2016
Trabeculectomy is performed as a treatment for glaucoma to lower intraocular pressure (IOP). The surgical procedure involves creating a channel through the wall of the eye. However scarring during wound healing can block this channel which will lead to th
- Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis
Cochrane Systematic Reviews, 16-Oct-2018
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) can reduce oedema, improve vision and prevent further visual loss. These drugs have replaced la
